TScan Therapeutics
TCRX
54 hedge funds and large institutions have $186M invested in TScan Therapeutics in 2023 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 12 increasing their positions, 5 reducing their positions, and 0 closing their positions.
154% more capital invested
Capital invested by funds: $73.2M → $186M (+$113M)
140% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 5
69% more funds holding
Funds holding: 32 → 54 (+22)
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
7.62% more ownership
Funds ownership: 65.66% → 73.28% (+7.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Aberdeen Group
Edinburgh,
United Kingdom
|
+$916K |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$506K |
| 3 |
Millennium Management
New York
|
+$454K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$398K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$383K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$458K |
| 2 |
Morgan Stanley
New York
|
-$113K |
| 3 |
LBA
Letko, Brosseau & Associates
Montreal,
Quebec, Canada
|
-$53.6K |
| 4 |
BlackRock
New York
|
-$39.9K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$1.67K |
TCRX Hedge Fund Activity: Q4 2023 in Review
54 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in TScan Therapeutics (TCRX) for Q4 2023, worth a combined $186M — up 154% from $73.2M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new TCRX positions and 0 closed out — a net gain of 22 holders — while 12 added to existing stakes and 5 trimmed.
The largest buyer was Aberdeen Group, opening a new position worth an estimated $916K. The largest seller was Adage Capital Partners, cutting an estimated $458K.
- 54 institutional investors held TScan Therapeutics (TCRX) as of Q4 2023, up from 32 in Q3 2023.
- Funds reported $186M of TScan Therapeutics stock for Q4 2023, up 154% quarter-over-quarter.
- 22 funds opened new TScan Therapeutics positions in Q4 2023 and 0 closed out, a net change of +22 holders.
- The largest TScan Therapeutics buyer in Q4 2023 was Aberdeen Group, an estimated $916K added.
- The largest TScan Therapeutics seller in Q4 2023 was Adage Capital Partners, an estimated $458K sold.
Based on aggregated 13F filings for Q4 2023.